MA45046A - Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules - Google Patents
Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellulesInfo
- Publication number
- MA45046A MA45046A MA045046A MA45046A MA45046A MA 45046 A MA45046 A MA 45046A MA 045046 A MA045046 A MA 045046A MA 45046 A MA45046 A MA 45046A MA 45046 A MA45046 A MA 45046A
- Authority
- MA
- Morocco
- Prior art keywords
- nanoliposomal
- irinotecan
- treatment
- small cell
- cell cancer
- Prior art date
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
- 229960004768 irinotecan Drugs 0.000 title 1
- 208000000649 small cell carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US201762474661P | 2017-03-22 | 2017-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45046A true MA45046A (fr) | 2019-03-27 |
Family
ID=59258274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045046A MA45046A (fr) | 2016-05-18 | 2017-05-17 | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| AU2016309002B2 (en) | 2015-08-20 | 2021-07-29 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment |
| HK1257220A1 (zh) | 2015-08-21 | 2019-10-18 | 益普生生物制药有限公司 | 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法 |
| RS67289B1 (sr) | 2015-10-16 | 2025-11-28 | Ipsen Biopharm Ltd | Stabilizacija farmaceutskih kompozicija kamptotecina |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101462819B1 (ko) * | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| US20120003294A1 (en) * | 2007-08-17 | 2012-01-05 | Celator Pharmaceuticals, Inc. | Fixed ratio camptothecens/platinum agents |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 MX MX2018013873A patent/MX394766B/es unknown
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Ceased
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en not_active Ceased
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX394766B (es) | 2025-03-24 |
| CA3023743A1 (en) | 2017-11-23 |
| EP3458059A1 (en) | 2019-03-27 |
| WO2017199093A1 (en) | 2017-11-23 |
| PH12018502422A1 (en) | 2019-03-11 |
| MX2018013873A (es) | 2019-02-14 |
| IL262656A (en) | 2018-12-31 |
| AU2017267449A1 (en) | 2018-11-15 |
| US20230000858A1 (en) | 2023-01-05 |
| SG10201912407YA (en) | 2020-02-27 |
| KR20190009319A (ko) | 2019-01-28 |
| UA125646C2 (uk) | 2022-05-11 |
| TWI791437B (zh) | 2023-02-11 |
| BR112018072988A2 (pt) | 2019-04-09 |
| JP2022010295A (ja) | 2022-01-14 |
| JP2020117548A (ja) | 2020-08-06 |
| TW201740946A (zh) | 2017-12-01 |
| CN109640995A (zh) | 2019-04-16 |
| JP2019516693A (ja) | 2019-06-20 |
| SG11201809788VA (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3488001A4 (en) | TREATMENT OF CANCER | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| EP3555077A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | |
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| EP3374502A4 (en) | METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES | |
| EP3432927A4 (en) | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT | |
| EP3377516A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| DK3209691T3 (da) | Sammensætninger til inducering af differentiering af myeloid-afledt suppresorcelle til behandling af cancer og infektiøse sygdomme | |
| EP3288382A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| EP3436002A4 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | |
| EP3285773A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| EP3448263A4 (en) | Electrotherapeutic treatment | |
| EP3432888A4 (en) | CANCER TREATMENT WITH TG02 | |
| EP3409744A4 (en) | SURFACE TREATMENT AGENT | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| EP3341391A4 (en) | COMPOSITIONS AND METHODS OF PAIN TREATMENT | |
| EP3359192A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| EP3389645A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3359255A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP3471717A4 (en) | Treatment of squamous cell carcinomas with inhibitors of erk | |
| MA47408A (fr) | Traitement du cancer | |
| EP3431566A4 (en) | SURFACE TREATMENT AGENT | |
| MA51823A (fr) | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |